No Data
Recent 5.1% Pullback Isn't Enough to Hurt Long-term JiangSu WuZhong Pharmaceutical Development (SHSE:600200) Shareholders, They're Still up 100% Over 5 Years
Huachuang Securities: The retail and social services sectors are experiencing a rebound in customer traffic, with both fundamentals and valuation recovering.
Looking ahead to 2025, the service consumer sector is experiencing a rapid turnaround and repair, with both the 'broad and profound' fundamentals and valuation repair taking effect, establishing a clear trend.
Minsheng Securities: In 24Q3, the commercial retail industry in the consumer sector was affected by demand-side pressure, leading to a slowdown in revenue and profit growth across multiple sectors.
The total retail sales of 24 companies in Q1-Q3 reached 35.36 trillion yuan, with a year-on-year growth of +3.35%. The total retail sales of a single company in Q3 reached 11.76 trillion yuan, with a year-on-year growth of +2.69%, showing a slower growth rate compared to the previous quarter.
Pinning Down JiangSu WuZhong Pharmaceutical Development Co., Ltd.'s (SHSE:600200) P/S Is Difficult Right Now
Announcement of Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. on the main operating data from January to September 2024
Jiangsu Wu Zhong Medicine Development Co., Ltd. Report for the third quarter of 2024
Investors Aren't Buying JiangSu WuZhong Pharmaceutical Development Co., Ltd.'s (SHSE:600200) Revenues
